While biotech/pharma is set to reach a high in investment dollars this year, the exits and growth of digital health are trumping traditional life science deals.
Are biotech and pharma losing steam to tech-infused investments into digital health and healthcare IT? We used CB Insights data to analyze both areas to understand the health and momentum of each sector.
Amount invested – biotech/pharma wins but digital health is growing fast
The biotech/pharma industry continues to grow with 2013 posting $4.8B+ in investment. $4.6B+ has already been deployed this year which suggests that biotech/pharma is poised to hit a 6-year high by the end of 2014. While biotech/pharma may win in absolute numbers, the digital health industry has had explosive growth since 2009, already breaking $3B this year. At the current rate of investment, digital health is on track to exceed $4B in funding, which represents a 987% increase since 2009, and a 91% increase since last year.
Number of deals – digital health shows promise, but falls flat
Digital health deaflow significantly increased between 2009 and 2013, even passing biotech/pharma last year with 492 deals which represented 51% growth from 2012. However, the industry hit a bit of speedbump in 2014 with deal activity falling fairly significantly. Biotech/pharma, on the other hand, has maintained consistent growth year-over-year since 2009, with 2014 scheduled to hit a high of 600+ deals assuming current deal run-rate. (data through Q3’14)
Number of exits – biotech/pharma remains dominant
Exits in the biotech/pharma industry continue to increase, with 2014 already reaching a high of 157 by Q3. Digital health on the other hand, has lost steam on the exit front similar to financing deal activity.
Largest exits – digital health wins the IPO battle
The biotech/pharma and digital health industries have both had quite a few successful billion dollar exits. Veeva Systems had an incredibly successful exit in 2013 that gave the company a market cap of $4.5B and has made it the most capital efficient exit of a VC-backed company in the last 2 years (ahead of WhatsApp, in fact). On the other hand Castlight Health, which had a multi-billion dollar opening valuation has fallen on harder times as the stock currently trades significantly lower than the approximately $40 price it had on its opening day.
Intrexon, a synthetic biology and genetics company, had the most successful IPO on the biotech/pharma side and was valued at over $2.3B by the end of its first day of trading. Though both sectors have successful exit records, the digital health companies amassed a valuation of more than $10B compared to the $6.3B on the pharma/biotech side.
*Analysis did not include debt or grant rounds
Which sector holds more promise for future growth? Leave your comments below
Want more healthcare investment and exit data? Sign up for a free account to the CB Insights venture capital database below
This report was created with data from CB Insights’ emerging technology insights platform, which offers clarity into emerging tech and new business strategies through tools like:
- Earnings Transcripts Search Engine & Analytics to get an information edge on competitors’ and incumbents’ strategies
- Patent Analytics to see where innovation is happening next
- Company Mosaic Scores to evaluate startup health, based on our National Science Foundation-backed algorithm
- Business Relationships to quickly see a company’s competitors, partners, and more
- Market Sizing Tools to visualize market growth and spot the next big opportunity